Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Cowen improves Biogen, doubles the price after the approval of Alzheimer’s drugs

Cowen improves Biogen, doubles the price after the approval of Alzheimer’s drugs



Biogen’s headquarters on Binney Street on Thursday, March 21, 2019 in Cambridge, Massachusetts.

Nikolai Charnetsky MediaNews Group | Getty Images

Significant approval of Biogen’s Alzheimer’s drug should be a big winner for the company, even if the treatment is used by only a small percentage of patients, according to investment company Cowen.

Shares of the company rose 38% on Monday after approval of the drug, named Aduhelm.

As stocks improved to outperform market indicators, Cowen analyst Phil Nado said in an investor̵

7;s note that stocks were rising.


Source link